Symmetry Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Symmetry Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,144	Closed	-$278K	–	108
2024 Q2	$278K	Buy	+1,144	New	+$181K	0.01%	423
2024 Q1	–	Sell	-1,144	Closed	-$224K	–	539
2023 Q4	$224K	Sell	1,144 -187	-14%	-$31.9K	0.01%	464
2023 Q3	$236K	Hold	1,331	–	–	0.01%	479
2023 Q2	$253K	Hold	1,331	–	–	0.01%	503
2023 Q1	$267K	Hold	1,331	–	–	0.01%	472
2022 Q4	$316K	Hold	1,331	–	–	0.02%	457
2022 Q3	$266K	Buy	+1,331	New	+$254K	0.02%	475
2022 Q2	–	Sell	-1,331	Closed	-$217K	–	546
2022 Q1	$217K	Hold	1,331	–	–	0.01%	554
2021 Q4	$226K	Hold	1,331	–	–	0.01%	577
2021 Q3	$264K	Hold	1,331	–	–	0.02%	580
2021 Q2	$226K	Buy	+1,331	New	+$195K	0.02%	625

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Symmetry Partners's ALNY Position: Q3 2024 in Review

Symmetry Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 1,144 shares — an estimated $278K sold.

Symmetry Partners first reported a position in ALNY in Q2 2021 and held it in 11 quarters. The position peaked at $316K in Q4 2022. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

Symmetry Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Symmetry Partners sold 1,144 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $278K.
Symmetry Partners first reported a position in Alnylam Pharmaceuticals in Q2 2021 and held it in 11 quarters.
Symmetry Partners's Alnylam Pharmaceuticals position peaked at $316K in Q4 2022.
567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Symmetry Partners's 13F filing for Q3 2024, filed 29 Oct 2024.